Sanofi(SNY) - 2023 Q4 - Earnings Call Presentation

Consumer Healthcare update Financial performance Outlook 2024 Appendices Q4 2023 Booster vaccines 22 Vaccines performance Polio/ Pertussis/Hib €434m +3.4% Influenza €741m -4.0% €20m -76.1% Meningitis and PPH franchises benefited from public order pattern in the quarter Specialty Care Vaccines GenMed RSV Toddler for 2nd season onwards Innovative vaccines for all target populations • Phase 3 start in Q1 2024 PCV (Prevnar) and Rotavirus (Rotateq) data from IQVIA DDD for private doses, and CDC data for public d ...